Current status of vaccine development for group b streptococcus

NeoReviews

Volumn 15, Issue 10, 2014, Pages e430-e438

  Puopolo, Karen M ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907964590     PISSN: None     EISSN: 15269906     Source Type: Journal    
DOI: 10.1542/neo.15-10-e430     Document Type: Article

References (63)

1. Stoll BJ, Hansen NI, Sánchez PJ, et al;Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis:the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817-826
2. Phares CR, Lynfield R, Farley MM, et al;Active Bacterial Core Surveillance/Emerging Infections Program Network. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA. 2008;299(17):2056-2065
3. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease:a public health perspective. MMWR Recomm Rep. 1996;45(RR-7):1-24
4. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. 2002;16;51(RR-11):1-22
5. Verani JR, McGee L, Schrag SJ;Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease-revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1-36
6. Schrag SJ, Zell ER, Lynfield R, et al;Active Bacterial Core Surveillance Team. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med. 2002;347(4):233-239
7. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2012. Available at:http://www.cdc.gov/abcs/reports-findings/survreports/gbs12.pdf. Accessed June 30, 2014
8. Puopolo KM, Madoff LC, Eichenwald EC. Early-onset group B streptococcal disease in the era of maternal screening. Pediatrics. 2005;115(5):1240-1246
9. Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med. 2009;360(25):2626-2636
10. Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis. 2005;41(6):839-847
11. Lancefield RC. A serological differentiation of specific types of bovine hemolytic streptococci (group B). J Exp Med. 1934;59(4):441-458
12. Rubens CE, Wessels MR, Heggen LM, Kasper DL. Transposon mutagenesis of type III group B streptococcus:correlation of capsule expression with virulence. Proc Natl Acad Sci U S A. 1987;84(20):7208-7212
13. Wessels MR, Rubens CE, BenedíVJ, Kasper DL. Definition of a bacterial virulence factor:sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A. 1989;86(22):8983-8987
14. Rubens CE, Wessels MR, Kuypers JM, Kasper DL, Weiser JN. Molecular analysis of two group B streptococcal virulence factors. Semin Perinatol. 1990;14(4 suppl 1):22-29
15. Doran KS, Nizet V. Molecular pathogenesis of neonatal group B streptococcal infection:no longer in its infancy. Mol Microbiol. 2004;54(1):23-31
16. Maisey HC, Doran KS, Nizet V. Recent advances in understanding the molecular basis of group B Streptococcus virulence. Expert Rev Mol Med. 2008;10:e27
17. Jiang SM, Cieslewicz MJ, Kasper DL, Wessels MR. Regulation of virulence by a two-component system in group B streptococcus. J Bacteriol. 2005;187(3):1105-1113
18. Rajagopal L, Clancy A, Rubens CE. A eukaryotic type serine/threonine kinase and phosphatase in Streptococcus agalactiae reversibly phosphorylate an inorganic pyrophosphatase and affect growth, cell segregation, and virulence. J Biol Chem. 2003;278(16):14429-14441
19. Klinzing DC, Ishmael N, Dunning Hotopp JC, et al. The twocomponent response regulator LiaR regulates cell wall stress responses, pili expression and virulence in group B Streptococcus. Microbiology. 2013;159(pt 7):1521-1534
20. Lancefield RC, McCarty M, Everly WN. Multiple mouseprotective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med. 1975;142(1):165-179
21. Madoff LC, Paoletti LC, Tai JY, Kasper DL. Maternal immunization of mice with group B streptococcal type III polysaccharidebeta C protein conjugate elicits protective antibody to multiple serotypes. J Clin Invest. 1994;94(1):286-292
22. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976;294(14):753-756
23. Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis. 2014;209(5):781-788
24. Baker CJ, Edwards MS, Kasper DL. Immunogenicity of polysaccharides from type III, group B Streptococcus. J Clin Invest. 1978;61(4):1107-1110
25. Baker CJ, Kasper DL. Group B streptococcal vaccines. Rev Infect Dis. 1985;7(4):458-467
26. Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL. Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. N Engl J Med. 1988;319(18):1180-1185
27. Edwards MS, Baker CJ, Kasper DL. Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus. J Infect Dis. 1979;140(6):1004-1008
28. Baker CJ, Kasper DL, Edwards MS, Schiffman G. Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens. N Engl J Med. 1980;303(4):173-178
29. Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest. 1996;98(10):2308-2314
30. Baker CJ, Paoletti LC, Wessels MR, et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J InfectDis. 1999;179(1):142-150
31. Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. J Infect Dis. 2000;182(4):1129-1138
32. Chen VL, Avci FY, Kasper DL. A maternal vaccine against group B Streptococcus:past, present, and future. Vaccine. 2013;31 (suppl 4):D13-D19
33. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharidetetanus toxoid conjugate vaccine. Vaccine. 2003;21(24):3468-3472
34. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged younger than 3 months:systematic review and meta-analysis. Lancet. 2012;379(9815):547-556
35. Edwards MS, Rench MA, Palazzi DL, Baker CJ. Group B streptococcal colonization and serotype-specific immunity in healthy elderly persons. Clin Infect Dis. 2005;40(3):352-357
36. Baker CJ, Rench MA, Paoletti LC, Edwards MS. Doseresponse to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine. 2007;25(1):55-63
37. Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Edwards MS, Kasper DL. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis. 2004;189(6):1103-1112
38. Palazzi DL, Rench MA, Edwards MS, Baker CJ. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis. 2004;190(3):558-564
39. Dutra VG, Alves VM, Olendzki AN, et al. Streptococcus agalactiae in Brazil:serotype distribution, virulence determinants and antimicrobial susceptibility. BMC Infect Dis. 2014;14(1):323
40. Kiely RA, Cotter L, Mollaghan AM, Cryan B, Coffey A, Lucey B. Emergence of group B Streptococcus serotype IV in women of child-bearing age in Ireland. Epidemiol Infect. 2011;139(2):236-238
41. Jannati E, Roshani M, Arzanlou M, Habibzadeh S, Rahimi G, Shapuri R. Capsular serotype and antibiotic resistance of group B streptococci isolated from pregnant women in Ardabil, Iran. Iran J Microbiol. 2012;4(3):130-135
42. Shabayek S, Abdalla S, Abouzeid AM. Serotype and surface protein gene distribution of colonizing group B streptococcus in women in Egypt. Epidemiol Infect. 2014;142(1):208-210
43. Lachenauer CS, Kasper DL, Shimada J, et al. Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis. 1999;179(4):1030-1033
44. Al-Sweih N, Hammoud M, Al-Shimmiri M, Jamal M, Neil L, Rotimi V. Serotype distribution and mother-to-baby transmission rate of Streptococcus agalactiae among expectant mothers in Kuwait. Arch Gynecol Obstet. 2005;272(2):131-135
45. Diedrick MJ, Flores AE, Hillier SL, Creti R, Ferrieri P. Clonal analysis of colonizing group B Streptococcus, serotype IV, an emerging pathogen in the United States. J Clin Microbiol. 2010;48 (9):3100-3104
46. Baker CJ, Rench MA, Fernandez M, Paoletti LC, Kasper DL, Edwards MS. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis. 2003;188(1):66-73
47. Bolduc GR, Baron MJ, Gravekamp C, Lachenauer CS, Madoff LC. The alpha C protein mediates internalization of group B Streptococcus within human cervical epithelial cells. Cell Microbiol. 2002;4(11):751-758
48. Pannaraj PS, Kelly JK, Rench MA, Madoff LC, Edwards MS, Baker CJ. Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease. Vaccine. 2008;26 (4):502-508
49. Gravekamp C, Kasper DL, Paoletti LC, Madoff LC. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines. Infect Immun. 1999;67(5):2491-2496
50. Jerlström PG, Talay SR, Valentin-Weigand P, Timmis KN, Chhatwal GS. Identification of an immunoglobulin A binding motif located in the beta-antigen of the c protein complex of group B streptococci. Infect Immun. 1996;64(7):2787-2793
51. Lachenauer CS, Baker CJ, Baron MJ, Kasper DL, Gravekamp C, Madoff LC. Quantitative determination of immunoglobulin G specific for group B streptococcal beta C protein in human maternal serum. J Infect Dis. 2002;185(3):368-374
52. Yang HH, Madoff LC, Guttormsen HK, Liu YD, Paoletti LC. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun. 2007;75(7):3455-3461
53. Liu GY, Nizet V. Extracellular virulence factors of group B streptococci. Front Biosci. 2004;9:1794-1802
54. Santillan DA, Andracki ME, Hunter SK. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase. Am J Obstet Gynecol. 2008;198:114e1-114e6
55. Brodeur BR, Boyer M, Charlebois I, et al. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. Infect Immun. 2000;68(10):5610-5618
56. Manning SD, Wood S, Kasha K, et al. Naturally occurring antibodies for the group B streptococcal surface immunogenic protein (Sip) in pregnant women and newborn babies. Vaccine. 2006;24(47-48):6905-6912
57. Martin D, Rioux S, Gagnon E, et al. Protection from group B streptococcal infection in neonatal mice by maternal immunization with recombinant Sip protein. Infect Immun. 2002;70(9):4897-4901
58. Xue G, Yu L, Li S, Shen X. Intranasal immunization with GBS surface protein Sip and ScpB induces specific mucosal and systemic immune responses in mice. FEMS Immunol Med Microbiol. 2010;58(2):202-210
59. Maione D, Margarit I, Rinaudo CD, et al. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science. 2005;309(5731):148-150
60. Johri AK, Paoletti LC, Glaser P, et al. Group B Streptococcus:global incidence and vaccine development. Nat Rev Microbiol. 2006;4(12):932-942
61. Paoletti LC, Guttormsen HK, Christian MS, Hoberman AM, McInnes P. Neither antibody to a group B streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits. Hum Vaccin. 2008;4(6):435-443
62. Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharideprotein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine. 2013;31(suppl 4):D52-D57
63. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J. 2011;30(11):937-941